A novel tool for rapidly identifying the genetic „fingerprints“ of cancer cells may enable future surgeons to more accurately remove brain tumors while a patient is in the operating room, new research reveals. Many cancer types can be identified by certain mutations, changes in the instructions encoded in the DNA of the abnormal cells. Led by a research team from NYU Langone Health, the new study describes the development of Ultra-Rapid droplet digital PCR, or UR-ddPCR, which the team found can measure the level of tumor cells in a tissue sample in only 15 minutes while also being able to detect small numbers of cancer cells (as few as five cells per square millimeter). The researchers say their tool is fast and accurate enough, at least in initial tests on brain tissue samples, to become the first practical tool of… 

The global organoid services market share is projected to grow from US$3.03 billion in 2023 to US$15.01 billion by 2031, driven by the increasing demand for personalized medicine and innovative drug screening services. According to a comprehensive report from The Insight Partners, „Organoids Services Market Size and Forecast 2023 – 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report“ The global organoid services market is observing significant growth owing to the surging popularity of personalized drugs and increasing demand for innovative drug screening services. The report carries out an in-depth analysis of market trends, key players, and future opportunities. The organoid services market scope entails an array of services that are expected to determine the market performance in the coming years.

Prolacta Bioscience, the world’s leading hospital provider of 100% human milk-based nutritional products, today announced the U.S. Food and Drug Administration (FDA) has approved Surgifort® human milk fortifier (human pasteurized) for term infants (> 37 weeks) following corrective surgery for the gastrointestinal disorder gastroschisis. Surgifort fortifier is the latest addition to Prolacta’s line of human milk-based nutritional products, and it is the first fortifier indicated for use in term babies. Gastroschisis is a birth defect where the intestines, and sometimes other organs, protrude through the abdominal wall. Similar to premature infants, term infants recovering from corrective gastroschisis surgery require high macronutrient intake for optimal growth.1 Surgifort fortifier is specifically formulated to deliver optimal protein and calories to promote growth. When Surgifort fortifier is mixed with term human milk, and given at an appropriate volume, clinicians can achieve nutrition that is within the recommendations…